- Home
- PROK vs FINW Comparison
PROK vs FINW Comparison
Compare PROK & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- FINW
- Stock Information
- Founded
- PROK 2015
- FINW 1999
- Country
- PROK United States
- FINW United States
- Employees
- PROK N/A
- FINW N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- FINW Commercial Banks
- Sector
- PROK Health Care
- FINW Finance
- Exchange
- PROK Nasdaq
- FINW Nasdaq
- Market Cap
- PROK 220.6M
- FINW 211.4M
- IPO Year
- PROK N/A
- FINW 2021
- Fundamental
- Price
- PROK $1.70
- FINW $17.68
- Analyst Decision
- PROK Buy
- FINW Buy
- Analyst Count
- PROK 5
- FINW 2
- Target Price
- PROK $4.50
- FINW $17.50
- AVG Volume (30 Days)
- PROK 437.3K
- FINW 17.7K
- Earning Date
- PROK 11-12-2024
- FINW 10-24-2024
- Dividend Yield
- PROK N/A
- FINW N/A
- EPS Growth
- PROK N/A
- FINW N/A
- EPS
- PROK N/A
- FINW 1.06
- Revenue
- PROK N/A
- FINW $69,238,000.00
- Revenue This Year
- PROK N/A
- FINW N/A
- Revenue Next Year
- PROK N/A
- FINW $10.71
- P/E Ratio
- PROK N/A
- FINW $16.71
- Revenue Growth
- PROK N/A
- FINW 4.86
- 52 Week Low
- PROK $1.12
- FINW $8.72
- 52 Week High
- PROK $4.44
- FINW $17.98
- Technical
- Relative Strength Index (RSI)
- PROK 43.50
- FINW 74.77
- Support Level
- PROK $1.95
- FINW $17.49
- Resistance Level
- PROK $2.27
- FINW $17.98
- Average True Range (ATR)
- PROK 0.18
- FINW 0.56
- MACD
- PROK 0.03
- FINW 0.03
- Stochastic Oscillator
- PROK 26.45
- FINW 84.94
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.